Recent reform efforts have pushed toward a better understanding of the distinction between exploratory and confirmatory research, and appropriate use of each. As some utilize more exploratory tools, it may be tempting to employ multiple linear regression models. In this paper, we advocate for the use of random forest (RF) models. RF is able to obtain better predictive performance than traditional regression, while also inherently protecting against overfitting as well as detecting nonlinear effects and interactions among predictors. Given the advantages of RF compared to other statistical procedures, it is a tool commonly used within a plethora of industries, including stock trading, banking, pharmaceuticals, and patient healthcare planning. However, we find RF is used within the field of psychology comparatively less frequently. In the current paper, we advocate for RF as an important statistical tool within the context of behavioral and psychological research. In hopes of increasing the use of RF in the field of psychology, we provide information pertaining to the limitations one might confront in using RF and how to overcome such limitations. Moreover, we discuss various methods for how to optimally utilize RF with psychological data, such as nonparametric modeling, interaction and nonlinearity detection, variable selection, prediction and classification modeling, and assessing parameters of Monte Carlo simulations. Throughout, we illustrate the use of RF with visualization strategies, aimed to make RF models more comprehensible and intuitive.

Download full-text PDF

Source
http://dx.doi.org/10.3758/s13428-022-01901-9DOI Listing

Publication Analysis

Top Keywords

random forest
8
paper advocate
8
field psychology
8
common uncommon
4
uncommon novel
4
novel applications
4
applications random
4
forest psychological
4
psychological reform
4
reform efforts
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Clinical trials should strive to yield results that are clinically meaningful rather than solely relying on statistical significance. However, the determination of clinical meaningfulness of dementia clinical trials lacks standardization and varies based on the trial's nature. To tackle this issue, a proposed approach involves assessing the time saved before reaching a specific threshold in cognitive status.

View Article and Find Full Text PDF

Background: Dementia poses a significant global crisis, yet 60% of cases go undetected, particularly among specific sub-populations. Timely diagnosis is crucial for implementing early intervention strategies. Challenges of current screening tools (e.

View Article and Find Full Text PDF

Background: Currently, the diagnosis of Alzheimer's disease dementia (ADD) is determined based on clinical criteria, as well as specific imaging and cerebrospinal fluid (CSF) biomarker profiles. However, healthcare professionals face a variety of challenges that hinder their application, such as the interpretation and integration or large amounts of data derived from neuropsychological assessment, the importance attributed to each source of information and the impact of unknown variables, among others. Therefore, this research focuses on the development of a computerized diagnostic tool based on Artificial Intelligence (AI), to strengthen the capacity of healthcare professionals in the identification and diagnosis of ADD.

View Article and Find Full Text PDF

Background: Speech impairment appears at early stages of Alzheimer's disease. A mobile voice recognition-based cognitive assessment tool, Shanghai Cognitive Screening (SCS), was developed for detecting mild cognitive impairment (MCI) and dementia in the community. The objective of this study is to investigate speech biomarkers associated with cognitive impairments based on SCS, and to evaluate the diagnostic accuracy of speech feature-based machine learning (ML) models for detecting MCI.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a progressive neurodegenerative condition, with considerable variation in disease progression from the mild cognitive impairment (MCI) stage. Predicting disease progression will support prognostic decisions and patient management. Here we designed a machine learning (ML) stack model, where a classifier was used to differentiate MCI progressors from non-progressors (i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!